Loading...

Radius Health

DB:1R8
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1R8
DB
$973M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The last earnings update was 56 days ago. More info.


Add to Portfolio Compare Print
1R8 Share Price and Events
7 Day Returns
-4.4%
DB:1R8
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-28.8%
DB:1R8
-5.6%
DE Biotechs
-4.5%
DE Market
1R8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Radius Health (1R8) -4.4% 16.2% 25.4% -28.8% -43% -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • 1R8 underperformed the Biotechs industry which returned -5.6% over the past year.
  • 1R8 underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
1R8
Industry
5yr Volatility vs Market

Value

 Is Radius Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Radius Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Radius Health.

DB:1R8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:1R8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 21%) (18.48%))
1.446
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.45
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.446 * 5.96%)
8.84%

Discounted Cash Flow Calculation for DB:1R8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Radius Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:1R8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.84%)
2019 -128.30 Analyst x3 -117.88
2020 -91.69 Analyst x3 -77.39
2021 -38.29 Analyst x2 -29.70
2022 -3.88 Analyst x2 -2.76
2023 88.32 Analyst x2 57.82
2024 152.37 Est @ 72.51% 91.64
2025 229.81 Est @ 50.83% 126.98
2026 311.73 Est @ 35.65% 158.25
2027 389.72 Est @ 25.02% 181.77
2028 458.25 Est @ 17.58% 196.37
Present value of next 10 years cash flows $585.11
DB:1R8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $458.25 × (1 + 0.23%) ÷ (8.84% – 0.23%)
$5,330.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,330.98 ÷ (1 + 8.84%)10
$2,284.45
DB:1R8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $585.11 + $2,284.45
$2,869.55
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $2,869.55 / 46.11
$62.24
DB:1R8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:1R8 represents 0.88408x of NasdaqGM:RDUS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88408x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 62.24 x 0.88408
€55.02
Value per share (EUR) From above. €55.02
Current discount Discount to share price of €18.65
= -1 x (€18.65 - €55.02) / €55.02
66.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Radius Health is available for.
Intrinsic value
>50%
Share price is €18.65 vs Future cash flow value of €55.02
Current Discount Checks
For Radius Health to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Radius Health's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Radius Health's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Radius Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Radius Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1R8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-4.88
NasdaqGM:RDUS Share Price ** NasdaqGM (2019-04-25) in USD $21.1
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Radius Health.

DB:1R8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:RDUS Share Price ÷ EPS (both in USD)

= 21.1 ÷ -4.88

-4.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Radius Health is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Radius Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Radius Health's expected growth come at a high price?
Raw Data
DB:1R8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
32.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Radius Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Radius Health's assets?
Raw Data
DB:1R8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.33
NasdaqGM:RDUS Share Price * NasdaqGM (2019-04-25) in USD $21.1
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:1R8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:RDUS Share Price ÷ Book Value per Share (both in USD)

= 21.1 ÷ 1.33

15.86x

* Primary Listing of Radius Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Radius Health is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Radius Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Radius Health has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Radius Health expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Radius Health expected to grow at an attractive rate?
  • Radius Health's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Radius Health's earnings growth is expected to exceed the Germany market average.
  • Radius Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1R8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1R8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 32.7%
DB:1R8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 27.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1R8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1R8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 517 6 87 4
2022-12-31 366 -74 -89 4
2021-12-31 322 -72 -136 6
2020-12-31 249 -89 -131 8
2019-12-31 170 -127 -162 8
DB:1R8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 99 -205 -221
2018-09-30 72 -204 -251
2018-06-30 58 -215 -259
2018-03-31 37 -224 -259
2017-12-31 22 -207 -254
2017-09-30 14 -204 -236
2017-06-30 1 -180 -224
2017-03-31 -159 -199
2016-12-31 -140 -183
2016-09-30 -130 -163
2016-06-30 -121 -145
2016-03-31 -101 -125

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Radius Health's earnings are expected to grow significantly at over 20% yearly.
  • Radius Health's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1R8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Radius Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1R8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.37 1.41 1.32 2.00
2022-12-31 -0.63 0.93 -2.41 4.00
2021-12-31 -1.80 0.14 -2.73 6.00
2020-12-31 -2.61 -1.50 -3.29 8.00
2019-12-31 -3.49 -2.47 -4.46 8.00
DB:1R8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -4.88
2018-09-30 -5.57
2018-06-30 -5.79
2018-03-31 -5.85
2017-12-31 -5.80
2017-09-30 -5.43
2017-06-30 -5.19
2017-03-31 -4.62
2016-12-31 -4.24
2016-09-30 -3.80
2016-06-30 -3.41
2016-03-31 -3.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Radius Health will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Radius Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Radius Health has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Radius Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Radius Health's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Radius Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Radius Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Radius Health's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Radius Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Radius Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1R8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 99.24 -221.34 186.08 98.00
2018-09-30 72.48 -251.26 193.10 96.78
2018-06-30 58.31 -259.30 197.38 90.75
2018-03-31 36.66 -258.85 198.76 84.24
2017-12-31 22.11 -254.24 188.84 80.92
2017-09-30 14.45 -235.94 167.24 81.92
2017-06-30 0.98 -224.28 138.21 88.93
2017-03-31 -199.28 104.21 97.23
2016-12-31 -182.80 79.76 105.19
2016-09-30 -163.32 61.66 104.05
2016-06-30 -145.40 50.88 94.82
2016-03-31 -124.93 39.69 84.20
2015-12-31 -101.53 31.41 67.67
2015-09-30 -86.25 24.84 57.62
2015-06-30 -75.40 19.22 53.22
2015-03-31 -69.08 16.29 47.56
2014-12-31 -71.48 13.67 45.72
2014-09-30 -70.82 10.23 45.62
2014-06-30 -78.49 9.02 47.34
2014-03-31 -85.73 7.39 52.97
2013-12-31 -78.16 6.83 60.54
2013-09-30 -85.24 7.90 65.49
2013-06-30 -81.24 8.20 64.12
2013-03-31 -78.78 8.64 62.38
2012-12-31 -83.12 9.17 54.96
2012-09-30 -59.19 8.18 46.38
2012-06-30 -50.05 7.48 39.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Radius Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Radius Health has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Radius Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Radius Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Radius Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Radius Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Radius Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Radius Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Radius Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Radius Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Radius Health Company Filings, last reported 3 months ago.

DB:1R8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 60.63 179.81 236.46
2018-09-30 95.05 176.18 234.13
2018-06-30 136.76 172.67 231.17
2018-03-31 195.18 169.28 235.54
2017-12-31 242.04 166.01 253.28
2017-09-30 305.84 162.76 468.08
2017-06-30 207.32 0.00 214.72
2017-03-31 262.10 0.00 282.11
2016-12-31 307.18 0.00 332.45
2016-09-30 352.39 0.00 369.83
2016-06-30 389.87 0.00 400.86
2016-03-31 426.18 0.00 437.31
2015-12-31 461.29 0.00 473.34
2015-09-30 488.53 0.00 500.79
2015-06-30 188.10 24.53 224.01
2015-03-31 206.95 24.46 234.17
2014-12-31 63.46 24.39 105.28
2014-09-30 23.39 24.32 68.51
2014-06-30 39.75 20.30 79.02
2014-03-31 -2.22 10.16 29.56
2013-12-31 -24.50 13.01 12.30
2013-09-30 -35.40 15.21 29.74
2013-06-30 -15.51 17.08 41.88
2013-03-31 -37.98 18.95 13.41
2012-12-31 -30.01 20.81 22.65
2012-09-30 -9.74 22.02 35.20
2012-06-30 7.35 22.92 45.87
  • Radius Health's level of debt (296.6%) compared to net worth is high (greater than 40%).
  • Radius Health had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Radius Health has sufficient cash runway for 1.2 years based on current free cash flow.
  • Radius Health has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 26.7% each year.
X
Financial health checks
We assess Radius Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Radius Health has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Radius Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Radius Health dividends. Estimated to be 0% next year.
If you bought €2,000 of Radius Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Radius Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Radius Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1R8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1R8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Radius Health has not reported any payouts.
  • Unable to verify if Radius Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Radius Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Radius Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Radius Health's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Radius Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Radius Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Radius Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Radius Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jesper Høiland
COMPENSATION $7,936,054
AGE 58
TENURE AS CEO 1.8 years
CEO Bio

Mr. Jesper Høiland, M.Sc. has been the Chief Executive Officer and President at Radius Health, Inc. since July 17, 2017 and serves as Director. Mr. Høiland served as an Executive Vice President of US at Novo Nordisk A/S since March 2015 until September 1, 2016. Mr. Høiland served as the President of Novo Nordisk, Inc. since August 1, 2013. Mr. Høiland served as Senior Vice President of International Operations at Novo Nordisk A/S. Mr. Hiland served as Member of Senior Management Board at Novo Nordisk A/S. He served as the Manager of International Operations at Novo Nordisk A/S. He served as Novo Nordisk’s head of International Operations where he oversaw all operations outside of Europe, China, Japan, Korea and North America. He has 30 years of experience in the biopharmaceutical industry across numerous senior leadership roles, geographies and therapeutic areas. He has extensive knowledge about the areas of endocrinology, biopharmaceuticals and women health as well as unique insights about US market access. He serves as a Director of Astion Pharma A/S. Mr. Høiland has an MSc in Management from Copenhagen Business School, Denmark, from 1985.

CEO Compensation
  • Insufficient data for Jesper to compare compensation growth.
  • Jesper's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Radius Health management team in years:

1.8
Average Tenure
57
Average Age
  • The average tenure for the Radius Health management team is less than 2 years, this suggests a new team.
Management Team

Jesper Høiland

TITLE
President
COMPENSATION
$8M
AGE
58
TENURE
1.8 yrs

Pepe Carmona

TITLE
CFO, Senior VP & Treasurer
COMPENSATION
$3M
AGE
46
TENURE
1.9 yrs

Brent Hatzis-Schoch

TITLE
Senior VP
COMPENSATION
$2M
AGE
53
TENURE
4 yrs

Nick Harvey

TITLE
COMPENSATION
$2M
AGE
57
TENURE
1.9 yrs

Stavros Manolagas

TITLE
Co-Founder & Member of the Scientific Advisory Board

John Potts

TITLE
Co-Founder & Member of the Scientific Advisory Board
AGE
86

Michael Rosenblatt

TITLE
Co-Founder
AGE
70

John Katzenellenbogen

TITLE
Co-Founder & Member of the Scientific Advisory Board

Elhan Webb

TITLE
Head of Investor Relations & External Communications
TENURE
1.3 yrs

Joe Kelly

TITLE
Senior Vice President of Sales & Marketing
AGE
49
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure and age of the Radius Health board of directors in years:

3.9
Average Tenure
67.5
Average Age
  • The tenure for the Radius Health board of directors is about average.
Board of Directors

Kurt Graves

TITLE
Chairman of the Board
COMPENSATION
$756K
AGE
50
TENURE
7.4 yrs

Jesper Høiland

TITLE
President
COMPENSATION
$8M
AGE
58
TENURE
1.8 yrs

Stavros Manolagas

TITLE
Co-Founder & Member of the Scientific Advisory Board

John Potts

TITLE
Co-Founder & Member of the Scientific Advisory Board
AGE
86

Michael Rosenblatt

TITLE
Co-Founder
AGE
70

John Katzenellenbogen

TITLE
Co-Founder & Member of the Scientific Advisory Board

Cecil Lyttle

TITLE
Chairman of Scientific Advisory Board
COMPENSATION
$30K
AGE
72
TENURE
6.8 yrs

Tony Rosenberg

TITLE
Director
COMPENSATION
$721K
AGE
65
TENURE
4.1 yrs

Cathy Friedman

TITLE
Director
COMPENSATION
$734K
AGE
58
TENURE
3.7 yrs

JP Garnier

TITLE
Director
COMPENSATION
$721K
AGE
71
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Radius Health insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
06. Mar 19 Buy Jessica Hopfield Individual 05. Mar 19 05. Mar 19 12,800 €17.02 €217,878
21. Dec 18 Buy Bellevue Asset Management AG Company 20. Dec 18 20. Dec 18 60,000 €12.68 €760,966
18. Dec 18 Buy Joseph Kelly Individual 17. Dec 18 17. Dec 18 3,000 €13.85 €41,545
17. Dec 18 Buy Bellevue Asset Management AG Company 14. Dec 18 14. Dec 18 60,000 €13.85 €830,732
30. Aug 18 Sell MPM Capital Company 09. Jul 18 24. Aug 18 -3,999,243 €25.73 €-73,236,973
22. Aug 18 Buy Bellevue Asset Management AG Company 20. Aug 18 20. Aug 18 60,000 €17.18 €1,030,750
17. Aug 18 Sell Farallon Capital Management, L.L.C. Company 31. Jul 18 13. Aug 18 -2,043,151 €21.17 €-37,811,640
16. Aug 18 Buy Bellevue Asset Management AG Company 14. Aug 18 15. Aug 18 169,363 €18.43 €3,116,644
10. Aug 18 Buy Bellevue Asset Management AG Company 08. Aug 18 08. Aug 18 60,000 €19.59 €1,175,395
30. Jul 18 Buy Bellevue Asset Management AG Company 27. Jul 18 27. Jul 18 50,000 €21.29 €1,064,687
26. Jul 18 Buy Bellevue Asset Management AG Company 25. Jul 18 25. Jul 18 50,000 €23.37 €1,168,372
13. Jun 18 Buy Bellevue Asset Management AG Company 11. Jun 18 11. Jun 18 50,000 €23.17 €1,158,419
24. May 18 Buy Bellevue Asset Management AG Company 23. May 18 23. May 18 40,000 €24.70 €988,075
23. May 18 Buy Bellevue Asset Management AG Company 21. May 18 21. May 18 60,000 €24.89 €1,493,626
X
Management checks
We assess Radius Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Radius Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Details
Name: Radius Health, Inc.
1R8
Exchange: DB
Founded: 2003
$873,454,318
46,108,197
Website: http://www.radiuspharm.com
Address: Radius Health, Inc.
950 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM RDUS New Common Stock Nasdaq Global Market US USD 06. Jun 2014
DB 1R8 New Common Stock Deutsche Boerse AG DE EUR 06. Jun 2014
Number of employees
Current staff
Staff numbers
432
Radius Health employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:28
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.